Intraocular dapiprazole for the reversal of mydriasis after extracapsular cataract extraction with intraocular lens implantation. Part I: Dose-response correlation.
Dapiprazole, an alpha-blocking miotic drug, was used intracamerally at the end of extracapsular cataract extraction with posterior chamber intraocular lens (IOL) implantation. The double-blind study included 120 patients divided into four groups of 30 eyes; the groups received balanced salt solution, 0.125%, 0.25%, or 0.5% intraocular dapiprazole after IOL implantation and before suturing. Pupillary diameter recordings were performed immediately before and a few minutes after drug injection and two, four, and eight hours after surgery. The results showed a significant reversal of mydriasis by intraocular dapiprazole, especially with the 0.25% and 0.5% concentrations which did not differ significantly in effectiveness and safety.
Ponte
F
F
Clinica Oculistica, Policlinico, Palermo, Italy.
Cillino
S
S
Faranda
F
F
Casanova
F
F
Cucci
F
F
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000867:Anterior Chamber / Q000187:drug effects; D002387:Cataract Extraction; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007910:Lenses, Intraocular; D008297:Male; D008875:Middle Aged; D010879:Piperazines; D011182:Postoperative Care; D011680:Pupil / Q000187:drug effects*; D014230:Triazoles / Q000008:administration & dosage*
D000317:Adrenergic alpha-Antagonists; D010879:Piperazines; D014230:Triazoles; C035289:dapiprazole